Pages that link to "Q34307354"

The following pages link to Long-term cultivation-independent microbial diversity analysis demonstrates that bacterial communities infecting the adult cystic fibrosis lung show stability and resilience (Q34307354):

Displaying 50 items.

• Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis (Q24188313) (← links)
• The pediatric microbiome and the lung (Q26851334) (← links)
• The cystic fibrosis lower airways microbial metagenome (Q28596642) (← links)
• The role of the bacterial microbiome in lung disease (Q33554623) (← links)
• Polymicrobial airway bacterial communities in adult bronchiectasis patients (Q33650443) (← links)
• Antibiotic management of lung infections in cystic fibrosis. I. The microbiome, methicillin-resistant Staphylococcus aureus, gram-negative bacteria, and multiple infections (Q33786154) (← links)
• Potentially pathogenic airway bacteria and neutrophilic inflammation in treatment resistant severe asthma (Q33793577) (← links)
• The metabolic footprint of the airway bacterial community in cystic fibrosis (Q33861701) (← links)
• The upper respiratory tract as a microbial source for pulmonary infections in cystic fibrosis. Parallels from island biogeography (Q33901596) (← links)
• Pseudomonas aeruginosa Alters Staphylococcus aureus Sensitivity to Vancomycin in a Biofilm Model of Cystic Fibrosis Infection (Q33916479) (← links)
• The microbiome in pediatric cystic fibrosis patients: the role of shared environment suggests a window of intervention (Q33960112) (← links)
• Pharmacokinetics and pharmacodynamics of aerosolized antibacterial agents in chronically infected cystic fibrosis patients (Q34297656) (← links)
• Changes in cystic fibrosis airway microbiota at pulmonary exacerbation (Q34353683) (← links)
• Serial analysis of the gut and respiratory microbiome in cystic fibrosis in infancy: interaction between intestinal and respiratory tracts and impact of nutritional exposures (Q34388328) (← links)
• Sputum biomarkers and the prediction of clinical outcomes in patients with cystic fibrosis. (Q34390999) (← links)
• Three clinically distinct chronic pediatric airway infections share a common core microbiota (Q34425654) (← links)
• Exploring the parallel development of microbial systems in neonates with cystic fibrosis (Q34468522) (← links)
• Characterization and quantification of the fungal microbiome in serial samples from individuals with cystic fibrosis (Q34536205) (← links)
• Phenotypic heterogeneity of Pseudomonas aeruginosa populations in a cystic fibrosis patient. (Q34661901) (← links)
• Interpreting infective microbiota: the importance of an ecological perspective. (Q34677317) (← links)
• The microbial community of the cystic fibrosis airway is disrupted in early life (Q34744222) (← links)
• Predominant pathogen competition and core microbiota divergence in chronic airway infection (Q34760447) (← links)
• Microbial communities in the respiratory tract of patients with interstitial lung disease. (Q34941172) (← links)
• Complexity, temporal stability, and clinical correlates of airway bacterial community composition in primary ciliary dyskinesia. (Q34997989) (← links)
• The microbiome of the upper airways: focus on chronic rhinosinusitis (Q35012395) (← links)
• High individuality of respiratory bacterial communities in a large cohort of adult cystic fibrosis patients under continuous antibiotic treatment (Q35074619) (← links)
• Assessment of airway microbiota and inflammation in cystic fibrosis using multiple sampling methods (Q35127881) (← links)
• Antimicrobial resistance in the respiratory microbiota of people with cystic fibrosis (Q35230652) (← links)
• The daily dynamics of cystic fibrosis airway microbiota during clinical stability and at exacerbation (Q35237897) (← links)
• The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial. (Q35472705) (← links)
• Impact of storage conditions on metabolite profiles of sputum samples from persons with cystic fibrosis (Q35569460) (← links)
• Lung microbiota across age and disease stage in cystic fibrosis (Q35605802) (← links)
• The bacterial microbiota in inflammatory lung diseases (Q35677622) (← links)
• Selective Sweeps and Parallel Pathoadaptation Drive Pseudomonas aeruginosa Evolution in the Cystic Fibrosis Lung (Q35761876) (← links)
• Cystic fibrosis lung microbiome: opportunities to reconsider management of airway infection (Q35763672) (← links)
• Respiratory microbiota resistance and resilience to pulmonary exacerbation and subsequent antimicrobial intervention (Q35837327) (← links)
• The cystic fibrosis microbiome in an ecological perspective and its impact in antibiotic therapy (Q35861377) (← links)
• Coculture of Staphylococcus aureus with Pseudomonas aeruginosa Drives S. aureus towards Fermentative Metabolism and Reduced Viability in a Cystic Fibrosis Model (Q35914177) (← links)
• Host-microbiome interactions in acute and chronic respiratory infections (Q35955467) (← links)
• The Dynamics of Disease Progression in Cystic Fibrosis (Q36036190) (← links)
• Linking microbiota and respiratory disease (Q36135913) (← links)
• Cystic fibrosis lung environment and Pseudomonas aeruginosa infection. (Q36213685) (← links)
• Airway Microbiota in Bronchoalveolar Lavage Fluid from Clinically Well Infants with Cystic Fibrosis. (Q36216240) (← links)
• Tobramycin-Treated Pseudomonas aeruginosa PA14 Enhances Streptococcus constellatus 7155 Biofilm Formation in a Cystic Fibrosis Model System (Q36575038) (← links)
• Culture-Based and Culture-Independent Bacteriologic Analysis of Cystic Fibrosis Respiratory Specimens (Q36620854) (← links)
• Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation (Q37072994) (← links)
• Microbial Communities of Conducting and Respiratory Zones of Lung-Transplanted Patients (Q37396846) (← links)
• Longitudinal metagenomic profiling of bovine milk to assess the impact of intramammary treatment using a third-generation cephalosporin (Q37428242) (← links)
• Interspecific small molecule interactions between clinical isolates of Pseudomonas aeruginosa and Staphylococcus aureus from adult cystic fibrosis patients (Q37510338) (← links)
• Unique microbial communities persist in individual cystic fibrosis patients throughout a clinical exacerbation (Q37677382) (← links)